- Home
- CGON vs PSNY Comparison
CGON vs PSNY Comparison
Compare CGON & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- PSNY
- Stock Information
- Founded
- CGON 2010
- PSNY 2017
- Country
- CGON United States
- PSNY Sweden
- Employees
- CGON N/A
- PSNY N/A
- Industry
- CGON
- PSNY Auto Manufacturing
- Sector
- CGON
- PSNY Consumer Discretionary
- Exchange
- CGON NYSE
- PSNY Nasdaq
- Market Cap
- CGON 2.4B
- PSNY 2.8B
- IPO Year
- CGON 2024
- PSNY N/A
- Fundamental
- Price
- CGON $28.45
- PSNY $0.86
- Analyst Decision
- CGON Strong Buy
- PSNY Hold
- Analyst Count
- CGON 8
- PSNY 8
- Target Price
- CGON $63.88
- PSNY $1.59
- AVG Volume (30 Days)
- CGON 819.4K
- PSNY 5.6M
- Earning Date
- CGON 02-02-2025
- PSNY 02-10-2025
- Dividend Yield
- CGON N/A
- PSNY N/A
- EPS Growth
- CGON N/A
- PSNY N/A
- EPS
- CGON N/A
- PSNY N/A
- Revenue
- CGON $684,000.00
- PSNY $2,046,740,000.00
- Revenue This Year
- CGON $165.75
- PSNY $40.97
- Revenue Next Year
- CGON $47.04
- PSNY $94.45
- P/E Ratio
- CGON N/A
- PSNY N/A
- Revenue Growth
- CGON 258.12
- PSNY N/A
- 52 Week Low
- CGON $25.77
- PSNY $0.61
- 52 Week High
- CGON $50.23
- PSNY $2.56
- Technical
- Relative Strength Index (RSI)
- CGON 31.50
- PSNY 29.32
- Support Level
- CGON $27.58
- PSNY $1.02
- Resistance Level
- CGON $36.73
- PSNY $1.21
- Average True Range (ATR)
- CGON 2.01
- PSNY 0.07
- MACD
- CGON -0.52
- PSNY -0.01
- Stochastic Oscillator
- CGON 9.51
- PSNY 2.03
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.